Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $120 from $100 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics reports Q3 EPS ($1.03), consensus (84c)
- Palvella Therapeutics Reports Q3 2025 Financial Results
- PVLA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Palvella Therapeutics price target raised to $110 from $73 at Chardan
- Palvella Therapeutics price target raised to $97 from $65 at TD Cowen